<DOC>
	<DOC>NCT00503204</DOC>
	<brief_summary>This is a Phase I, open-label, multi-centre study designed to assess the safety and tolerability of Cediranib in combination with lomustine in patients with primary recurrent malignant brain tumour.</brief_summary>
	<brief_title>Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<criteria>Primary recurrent malignant brain tumour for whom lomustine would be standard therapy diagnosis &amp; stage Patients received no more than 2 previous systemic chemotherapy regimes Life Expectancy &gt; 12 weeks Patients must be at least 3 months from the completion of cranial radiation therapy History of poorly controlled high blood pressure Recent major surgery prior to entry into the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>cancer</keyword>
	<keyword>tumor</keyword>
	<keyword>advance solid tumour</keyword>
	<keyword>glioblastoma</keyword>
	<keyword>malignant brain tumour</keyword>
</DOC>